TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms

Stopped The clinical trial is terminated after the completion of phase I without moving to Phase II.

Conditions

• Safety
• Tolerability
• Feasibility
• Treatment Efficacy

Interventions

• DRUG: MDG1011
• OTHER: Investigator Choice therapy

Sponsor

Medigene AG